ClinVar Miner

Submissions for variant NM_005373.3(MPL):c.317C>T (p.Pro106Leu)

dbSNP: rs750046020
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255329 SCV000321906 pathogenic not provided 2023-07-06 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect with abnormal subcellular distribution of receptors and impaired glycosylation (Stockklausner et al, 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28034873, 30553997, 23351976, 31589614, 34308104, 35791502, 31135094, 35112413, 26077850, 28955303, 28979237, 28408900, 30318940, 30996850, 31092065, 30183354, 31808840, 33777803, 28444727, 33712866, 27884173, Mutairi_article_2023, 25538044, 34131895, 19036112)
Invitae RCV000814672 SCV000955091 pathogenic Congenital amegakaryocytic thrombocytopenia; Essential thrombocythemia 2024-01-16 criteria provided, single submitter clinical testing This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 106 of the MPL protein (p.Pro106Leu). This variant is present in population databases (rs750046020, gnomAD 0.04%). This missense change has been observed in individual(s) with autosomal recessive MPL-related conditions (PMID: 19036112, 25538044). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 265248). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MPL protein function. Experimental studies have shown that this missense change affects MPL function (PMID: 25538044). For these reasons, this variant has been classified as Pathogenic.
Al Jalila Children's Genomics Center, Al Jalila Childrens Speciality Hospital RCV001731468 SCV001984330 likely pathogenic Thrombocythemia 2 2020-11-18 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000255329 SCV002023507 likely pathogenic not provided 2023-09-25 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000255329 SCV002069100 likely pathogenic not provided 2019-07-19 criteria provided, single submitter clinical testing DNA sequence analysis of the MPL gene demonstrated a sequence change, c.317C>T, in exon 3 that results in an amino acid change, p.Pro106Leu. This sequence change has been described in the EXAC database with a low population frequency of 0.005% (dbSNP rs750046020) and has previously been described in patients with familial thrombocytosis in the homozygous state (El-Harith el-HA, et al., 2009; Stockklausner C, et al., 2012). Heterozygous carriers presented with normal platelet counts or mild thrombocytosis (El-Harith el-HA, et al., 2009; Stockklausner C, et al., 2012). The p.Pro106Leu change affects a highly conserved amino acid residue located in a domain of the MPL protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Pro106Leu substitution.
3billion RCV002250607 SCV002520973 likely pathogenic Congenital amegakaryocytic thrombocytopenia 2022-05-22 criteria provided, single submitter clinical testing The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.008%). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000265248). The variant has been observed in multiple, similarly affected unrelated individuals (PMID: 19036112). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
Fulgent Genetics, Fulgent Genetics RCV002479991 SCV002800513 likely pathogenic Congenital amegakaryocytic thrombocytopenia; Primary myelofibrosis; Thrombocythemia 2 2021-08-10 criteria provided, single submitter clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center RCV001731468 SCV004101784 pathogenic Thrombocythemia 2 2023-11-14 criteria provided, single submitter clinical testing MPL, a transmembrane protein receptor, is frequently mutated in myeloproliferative neoplasms including essential thrombocytosis and myelofibrosis. The MPL P106L mutation previously reported as pathogenic/likely pathogenic with strong evidence in ClinVar, The p.Pro106Leu change affects a highly conserved amino acid residue located in a domain of the MPL protein that is known to be functional. In-silico pathogenicity prediction tools, The presence of a MPL P106L mutation strongly supports a diagnosis of essential thrombocythemia.This variant has been classified as Pathogenic.
PreventionGenetics, part of Exact Sciences RCV004542964 SCV004770411 pathogenic MPL-related disorder 2024-02-15 criteria provided, single submitter clinical testing The MPL c.317C>T variant is predicted to result in the amino acid substitution p.Pro106Leu. This variant has a minor allele frequency of up to 2.6% in Saudi Arabians (Abouelhoda et al. 2016. PubMed ID: 27884173. Table S5), and is a frequent MPL pathogenic variant in the Arab population, leading to thrombocytosis in homozygotes and occasionally mild thrombocytosis in some heterozygous carriers (El-Harith et al. 2009. PubMed ID: 19036112). Functional analyses suggest that the MPL p.Pro106Leu change causes thrombocytosis due to an incomplete trafficking defect (Stockklausner et al. 2015. PubMed ID: 25538044). Expression of the variant MPL protein in vivo in mice partially reproduced the phenotype observed in homozygous patients (Favale et al. 2016. PubMed ID: 28034873). This variant is reported in 0.043% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic.
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center RCV003992253 SCV004810068 likely pathogenic Congenital amegakaryocytic thrombocytopenia 1 2024-04-04 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.